Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use-Results Survey of VELEXBRU in Relapsed or Refractory Primary Central Nervous System Lymphoma
jRCT2011210002Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ono Pharmaceutical. Primary endpoints: Occurrence of adverse drug reactions and infections, Occurrence of adverse drug reactions related to specified safety concerns and 1 more. Started May 2020; status: completed.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT2011210002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210002.